Gorzelak-Pabis P, Zyzak S, Krewko L, Broncel M. Assessment of the mean time in the therapeutic INR range and the SAME-TT2R2 score in patients with atrial brillation and cognitive impairment. Polskie Archiwum Medycyny Wewnetrznej. 2016;126(7-8):494-501. 179. Lip GY, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial brillation. Chest. 2014;146(3):719-726. 180. Lobos-Bejarano JM, Barrios V, Polo-Garcia J, et al. Evaluation of SAMe-TT2R2 score and other clinical factors in uencing the quality of anticoagulation therapy in non-valvular atrial brillation: a nationwide study in Spain. Current Medical Research And Opinion. 2016;32(7):1201-1207. 181. Poli D, Antonucci E, Testa S, Lip GY. A prospective validation of the SAME-TT2R 2 score: how to identify atrial brillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med. 2014;9(4):443-447. 182. Roldan V, Cancio S, Galvez J, et al. The SAMe-TT2R2 score predicts poor anticoagulation control in AF patients: a prospective real-world inception cohort study. Am J Med. 2015;128(11):1237- 1243. 183. Ruiz-Ortiz M, Bertomeu V, Cequier A, Marin F, Anguita M. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial brillation patients on vitamin K antagonists. Thromb Haemost. 2015;114(4):695-701. 184. Skov J, Bladbjerg EM, Bor MV, Gram J. SAMeTT(2)R(2) does not predict time in therapeutic range of the international normalized ratio in patients attending a high-quality anticoagulation clinic. Chest. 2014;145(1):187-188. 185. Szymanski FM, Lip GY, Filipiak KJ, Platek AE, Karpinski G. Usefulness of the SAME-TT2R2 score to predict anticoagulation control on VKA in patients with atrial brillation and obstructive sleep apnea. Int J Cardiol. 2016;204:200-205. 186. Abumuaileq RR, Abu-Assi E, Raposeiras-Roubin S, et al. 